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A novel strain of human coronaviruses, named by the International 
Committee on Taxonomy of Viruses (ICTV)1 as the severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged and 
caused an infectious disease. This disease has recently been referred 
to by the World Health Organisation (WHO) as the “coronavirus 
disease 2019” (COVID-19). Since the first report of this disease in 
December 2019 in Wuhan, China,2,3 COVID-19 has aggressively 
spread across the globe. WHO declared it a pandemic on March 11.
COVID-19 presents with many different clinical manifestations, 
ranging from asymptomatic cases to mild and severe disease, with 
or without pneumonia.4 Patients with common allergic conditions 
do not develop additional distinct symptoms and do not seem to 
be at an increased risk of severe disease. Allergic children show a 
mild course, like other children.5 COVID-19 cases with pre-existing 
COPD, or complicated by secondary bacterial pneumonia, are more 
severe, and this may be due to a complex immune pathogenesis.
Whether systemic corticosteroids have a deleterious effect on 
COVID-19 infection is still a matter of discussion. Clinical evidence 
does not support corticosteroid treatment for SARS-CoV-2 pneu-
monia.6 Moreover, corticosteroid therapy in patients with MERS 
(Middle East respiratory syndrome) was not associated with a dif-
ference in mortality after adjustment for time-varying confounders 
but was associated with delayed MERS coronavirus RNA clearance.7 
In accordance with current WHO guidance,8 it has been proposed 
that corticosteroids should not be used for SARS-CoV-2 -induced 
lung injury or shock, except in the setting of a clinical trial. However, 
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a team of front-line physicians from China had a different perspec-
tive.9 Given the inconclusive evidence and urgent clinical demand, 
physicians from the Chinese Thoracic Society have developed an 
expert consensus statement on the use of corticosteroids in SARS-
CoV-2 pneumonia that may allow the restricted use of low doses of 
corticosteroids for a short duration.10
Concerning inhaled corticosteroids in asthma, the Global 
Initiative for Asthma (GINA) recently stated the following (https://
ginas thma.org/recom menda tions -for-inhal ed-asthm a-contr oller 
-medic ation s/): “Some sources have suggested that “corticosteroids” 
should be avoided during the for SARS-CoV-2 epidemic. This advice 
is about the use of oral corticosteroids unless there is a clear indi-
cation for their use. However, patients with asthma should not stop 
their prescribed inhaled corticosteroid controller medication (or pre-
scribed oral corticosteroids). Stopping inhaled corticosteroids often 
leads to potentially dangerous worsening of asthma, and avoiding 
oral corticosteroids during severe asthma attacks may have serious 
consequences. Long-term oral corticosteroids may sometimes be re-
quired to treat severe asthma, and it may be dangerous to stop them 
suddenly. Always discuss with your doctor or nurse before stopping 
any asthma medication. Keep taking your inhaled asthma controller 
medication, and if your asthma gets worse, follow the instructions 
on your asthma action plan for how to change your asthma medica-
tions and when to seek medical help.”
Some scientific societies have made recommendations for an-
osmia and have proposed the use of intranasal corticosteroids. 
However, the French Agency (Direction Générale de la Santé) has 
contraindicated their use in anosmia and ageusia without nasal ob-
struction.11 They have extended the contraindication to saline wash-
ing since this could promote viral dissemination.
ARIA and EAACI followed the example of the Dutch ENT Society 
and sent a questionnaire to all ARIA members regarding the recom-
mendations for allergic rhinitis and anosmia. ARIA and EAACI are pro-
posing a joint statement following the results of the questionnaire.
1  | Anecdotal  evidence
In the Wuhan Children's hospital, there were about 40 paediatric 
COVID-19 cases with AR. Among these cases, approximately one 






1 Currently, nasal corticosteroid spray can be continued in 
the hay fever season.
175 (91.6%) 4 (2.2%) 3 (1.5%) 9 (4.7%)
2 Stopping local nasal corticoid spray is not advised: 
suppression of the immune system has not been proven, 
and more sneezing after stopping means more spreading 
of the Coronavirus.
173 (90.6%) 4 (2.2%) 3 (1.5%) 11 (5.8%)
3 Prescribing local nasal spray against anosmia due to 
Corona infection does not make sense.
100 (51.6%) 3 (1.5%) 0 88 (47.5%)
F I G U R E  1   List of countries with at least one answer to the questionnaire [Color figure can be viewed at wileyonlinelibrary.com]
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third used intranasal steroids regularly as before, the other two 
thirds did not. It was observed in these two patient groups that there 
was no difference in the severity and prognosis of COVID-19 and 
that all of them recovered well. (Personal communication Yadong 
Gao and Hui Du, Unpublished data).
2  | Quest ionnaire
A Delphi process was initiated by Anna Bedbrook who sent the three 
questions proposed by the Dutch ENT Society to the entire ARIA 
database (509 members, 84 countries), asking members to agree, 
somewhat disagree or completely disagree. After 48 hours, 209 re-
plies were received from 61 countries (Table 1 and Figure 1).
Q3 led to too many unanswered comments and could not be con-
sidered. Moreover, the scientific basis for this recommendation is 
lacking.
3  | Recommendations
With the current knowledge, in patients with COVID-19 infection, 
intranasal corticosteroids (including spray) can be continued in 
allergic rhinitis at the recommended dose.
Stopping local intranasal corticosteroids is not advised. Suppression 
of the immune system has not been proven and more sneezing 
after stopping means more spreading of the Coronavirus.
These recommendations are conditional since there is a paucity of 
data and they should be revised regularly with new knowledge.
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